Trial ID or NCT#

NCT00000803

Status

not recruiting iconNOT RECRUITING

Purpose

To determine the safety and anti-HIV activity of delavirdine mesylate ( U-90152 ) in combination with zidovudine ( AZT ) and/or didanosine ( ddI ) versus AZT/ddI combination. U-90152 has demonstrated anti-HIV activity. Since the combination of this drug with either AZT or ddI has synergistic inhibitory activity against HIV-1 in vitro, and triple therapy appears to have greater inhibitory activity against HIV-1 in vitro than dual therapy, the use of U-90152 in combination with AZT and/or ddI may improve the benefits of these drugs in persons with HIV disease.

Official Title

A Phase II Double-Blind Study of Delavirdine Mesylate ( U-90152 ) in Combination With Zidovudine ( AZT ) and/or Didanosine ( ddI ) Versus AZT and ddI Combination Therapy

Eligibility Criteria

Ages Eligible for Study: Older than 13 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Sanjiv Sam Gambhir, MD, PhD

Contact us to find out if this trial is right for you.

CONTACT

SPECTRUM